165 related articles for article (PubMed ID: 37963636)
1. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx.
Gandhi S; Opyrchal M; Grimm MJ; Slomba RT; Kokolus KM; Witkiewicz A; Attwood K; Groman A; Williams L; Tarquini ML; Wallace PK; Soh KT; Minderman H; Maguire O; O'Connor TL; Early AP; Levine EG; Kalinski P
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963636
[TBL] [Abstract][Full Text] [Related]
2. Helicase-Driven Activation of NFκB-COX2 Pathway Mediates the Immunosuppressive Component of dsRNA-Driven Inflammation in the Human Tumor Microenvironment.
Theodoraki MN; Yerneni S; Sarkar SN; Orr B; Muthuswamy R; Voyten J; Modugno F; Jiang W; Grimm M; Basse PH; Bartlett DL; Edwards RP; Kalinski P
Cancer Res; 2018 Aug; 78(15):4292-4302. PubMed ID: 29853604
[TBL] [Abstract][Full Text] [Related]
3. Functional reprogramming of human prostate cancer to promote local attraction of effector CD8(+) T cells.
Muthuswamy R; Corman JM; Dahl K; Chatta GS; Kalinski P
Prostate; 2016 Sep; 76(12):1095-105. PubMed ID: 27199259
[TBL] [Abstract][Full Text] [Related]
4. Phase I Trial Combining Chemokine-Targeting with Loco-Regional Chemoimmunotherapy for Recurrent, Platinum-Sensitive Ovarian Cancer Shows Induction of CXCR3 Ligands and Markers of Type 1 Immunity.
Orr B; Mahdi H; Fang Y; Strange M; Uygun I; Rana M; Zhang L; Suarez Mora A; Pusateri A; Elishaev E; Kang C; Tseng G; Gooding W; Edwards RP; Kalinski P; Vlad AM
Clin Cancer Res; 2022 May; 28(10):2038-2049. PubMed ID: 35046055
[TBL] [Abstract][Full Text] [Related]
5. A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity.
Fujimoto K; Karuppuchamy T; Takemura N; Shimohigoshi M; Machida T; Haseda Y; Aoshi T; Ishii KJ; Akira S; Uematsu S
J Immunol; 2011 Jun; 186(11):6287-95. PubMed ID: 21525388
[TBL] [Abstract][Full Text] [Related]
6. Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.
Glajcar A; Łazarczyk A; Tyrak KE; Hodorowicz-Zaniewska D; Streb J; Okoń K; Szpor J
Virchows Arch; 2021 Nov; 479(5):871-882. PubMed ID: 34117905
[TBL] [Abstract][Full Text] [Related]
7. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
8. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.
Muthuswamy R; Wang L; Pitteroff J; Gingrich JR; Kalinski P
J Immunother Cancer; 2015; 3():6. PubMed ID: 25806105
[TBL] [Abstract][Full Text] [Related]
9. CCL1 is a major regulatory T cell attracting factor in human breast cancer.
Kuehnemuth B; Piseddu I; Wiedemann GM; Lauseker M; Kuhn C; Hofmann S; Schmoeckel E; Endres S; Mayr D; Jeschke U; Anz D
BMC Cancer; 2018 Dec; 18(1):1278. PubMed ID: 30572845
[TBL] [Abstract][Full Text] [Related]
10. Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.
Francis L; Guo ZS; Liu Z; Ravindranathan R; Urban JA; Sathaiah M; Magge D; Kalinski P; Bartlett DL
Oncotarget; 2016 Apr; 7(16):22174-85. PubMed ID: 26956047
[TBL] [Abstract][Full Text] [Related]
11. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
12. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
13. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
14. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
Bronger H; Kraeft S; Schwarz-Boeger U; Cerny C; Stöckel A; Avril S; Kiechle M; Schmitt M
Breast Cancer Res; 2012 Feb; 14(1):R30. PubMed ID: 22333315
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
16. Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Bretz AC; Parnitzke U; Kronthaler K; Dreker T; Bartz R; Hermann F; Ammendola A; Wulff T; Hamm S
J Immunother Cancer; 2019 Nov; 7(1):294. PubMed ID: 31703604
[TBL] [Abstract][Full Text] [Related]
17. NFκB-Activated COX2/PGE
Ibrahim OM; Basse PH; Jiang W; Guru K; Chatta G; Kalinski P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809455
[TBL] [Abstract][Full Text] [Related]
18. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
19. Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents.
Obermajer N; Urban J; Wieckowski E; Muthuswamy R; Ravindranathan R; Bartlett DL; Kalinski P
Nat Protoc; 2018 Feb; 13(2):335-357. PubMed ID: 29345636
[TBL] [Abstract][Full Text] [Related]
20. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]